AVP-923 will Help Control the Inappropriate Emotions Associated with Multiple Sclerosis
Apr 15, 2005 - 11:05:00 AM
|
|
|
This is the first drug designed specifically for this condition. The only treatment now is antidepressants, which can have unpleasant side effects.
|
By Akanksha, Pharmacology Correspondent,
[RxPG] Now people with multiple sclerosis (MS) can have a better control over their emotions,thanks to the latest research scheduled to be presented at the American Academy of Neurology 57th Annual Meeting in Miami Beach, Fla., April 9 16, 2005.
Pseudobulbar affect, is a condition that results in episodes of uncontrollable laughing or crying that may be inappropriate or not related to the situation. The condition can also occur with other neurological disorders such as amyotrophic lateral sclerosis (ALS), Alzheimers disease, stroke, and brain injury.
For the study, 150 people with MS and pseudobulbar affect received either the drug AVP-923, which is a combination of the drugs dextromethorphan hydrobromide and quinidine sulfate, or a placebo for 12 weeks.
The study participants kept a diary tracking the number of laughing/crying episodes they experienced each day, as well as any side effects, and were assessed at four clinic visits.
Of those taking the drug, 84 percent reported improvement in the condition, compared to 49 percent of those on placebo. Those taking the drug had 46 percent fewer emotional episodes during the study than those who received the placebo. They also reported overall improvement in the condition and improvement in their quality of life, quality of relationships, and amount of pain they experienced. Those taking the drug reported the side effect of dizziness more often than those taking the placebo did.
This is the first drug designed specifically for this condition, said neurologist Hillel Panitch, MD, of the University of Vermont College of Medicine in Burlington, VT. The only treatment now is antidepressants, which can have unpleasant side effects.
Panitch said the treatment showed improvements as early as the first week of treatment.
Publication:
American Academy of Neurology
On the web:
www.aan.com 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Multiple Sclerosis Newsletter
|
|
|
|
Additional information about the news article
|
The study was supported by Avanir Pharmaceuticals, which is developing the drug AVP-923.
The American Academy of Neurology, an association of more than 18,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, epilepsy, multiple sclerosis, Parkinsons disease, and stroke.
For more information about the American Academy of Neurology, visit http://www.aan.com.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
